<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01386645</url>
  </required_header>
  <id_info>
    <org_study_id>1R01DK092568-01</org_study_id>
    <nct_id>NCT01386645</nct_id>
  </id_info>
  <brief_title>Effect of Dietary Glycemic Index on Beta-cell Function</brief_title>
  <acronym>GIdiet</acronym>
  <official_title>Effect of Dietary Glycemic Index on Beta-cell Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Institute for Biomedical and Clinical Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VA Puget Sound Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Seattle Institute for Biomedical and Clinical Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will determine if increasing the highs and lows of blood glucose levels (glycemic&#xD;
      variability) impairs insulin secretion in people with impaired glucose tolerance and/or&#xD;
      impaired fasting glucose who are at risk for developing type 2 diabetes. Furthermore, the&#xD;
      study will determine whether changes in beta-cell function are associated with glycemic&#xD;
      variability and whether they are mediated by oxidative stress. To decrease or increase&#xD;
      glycemic variability the study will provide subjects with special diets containing either low&#xD;
      or high glycemic index foods respectively for 4 weeks. To determine if oxidative stress is a&#xD;
      mediator, subjects on the high glycemic index diet will take either placebo or the&#xD;
      anti-oxidant N-acetylcysteine. The study will address the hypothesis that increased glycemic&#xD;
      variability results in increased oxidative stress and thereby exacerbates beta-cell&#xD;
      dysfunction in individuals with impaired glucose tolerance and/or impaired fasting glucose.&#xD;
      The findings may have important implications for the development of effective strategies&#xD;
      aimed at the prevention and treatment of type 2 diabetes. In addition, understanding the&#xD;
      contribution of dietary glycemic index to beta-cell dysfunction in subjects with pre-diabetes&#xD;
      may have a significant public health impact, including changes to dietary counseling and&#xD;
      promotion of healthier eating patterns.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 diabetes is a major health problem in the United States affecting millions of people.&#xD;
      It is caused by failure of the pancreatic beta-cells to secrete enough insulin resulting in&#xD;
      high blood glucose levels. People with impaired glucose tolerance (IGT) and impaired fasting&#xD;
      glucose have elevated glucose levels and are at increased risk for progressing to type 2&#xD;
      diabetes. The long-term objectives of this research are to better understand the factors that&#xD;
      contribute to the loss of beta-cell function and impaired insulin secretion. High glucose&#xD;
      levels have been shown to impair beta-cell function by causing oxidative stress, and&#xD;
      oscillating high glucose levels increase oxidative stress even more than continuous high&#xD;
      glucose. Diets containing foods with a high glycemic index (GI) increase the glycemic load&#xD;
      (GL) of the diet and post-prandial glucose levels. Therefore, high GL (HGL) diets could be&#xD;
      potentially damaging to the beta-cell by increasing glucose fluctuations and oxidative&#xD;
      stress. Conversely, low GL (LGL) diets may be beneficial. The study explores the hypothesis&#xD;
      that increased glycemic variability results in increased oxidative stress and thereby&#xD;
      exacerbates beta-cell dysfunction in people with pre-diabetes.&#xD;
&#xD;
      Specific Aim 1: Determine if a HGL diet worsens and a LGL diet improves beta-cell function&#xD;
      compared to a baseline control diet in subjects with pre-diabetes.&#xD;
&#xD;
      Specific Aim 2: Determine if increased glycemic variability on the HGL diet is associated&#xD;
      with decreased beta-cell function and conversely if decreased glycemic variability on the LGL&#xD;
      diet is associated with improved beta-cell function in subjects with pre-diabetes.&#xD;
&#xD;
      Specific Aim 3: Determine if oxidative stress induced by a HGL diet mediates decreases in&#xD;
      beta-cell function by determining if 1) systemic markers of oxidative stress are associated&#xD;
      with beta-cell function; 2) if the relationship between glycemic variability and beta-cell&#xD;
      function is at least partially explained by oxidative stress; and 3) the anti-oxidant&#xD;
      N-acetylcysteine (NAC) prevents decreases in beta-cell function on a HGL diet.&#xD;
&#xD;
      Study design: The study will be a randomized, parallel-design feeding study in men and women&#xD;
      with pre-diabetes. Subjects will be randomly assigned to one of 3 separate arms (n=20/arm):&#xD;
      1) 4 weeks on a LGL diet (GI&lt;35); 2) 4 weeks on a HGL diet (GI&gt;70) + placebo twice daily; or&#xD;
      3) 4 weeks on a HGL diet (GI&gt;70) + NAC 1200 mg twice daily. Subjects will be studied after a&#xD;
      2 week baseline control diet with a moderate glycemic load (GI 55-58) for comparison and all&#xD;
      diets will be weight stable with the same macronutrient composition (55% carbohydrate/30%&#xD;
      fat/15% protein). Beta-cell function will be assessed by both a frequently sampled&#xD;
      intravenous glucose tolerance test and a meal test. Glycemic variability will be assessed by&#xD;
      a Continuous Glucose Monitoring System and glycemic control by fructosamine. Markers of&#xD;
      oxidative stress will be measured.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">August 1, 2019</completion_date>
  <primary_completion_date type="Actual">August 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disposition Index</measure>
    <time_frame>4 weeks</time_frame>
    <description>The disposition index generated from an intravenous glucose tolerance test (insulin sensitivity x the acute insulin response to intravenous glucose) is a measure of beta-cell function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urine F2alpha Isoprostanes</measure>
    <time_frame>4 weeks</time_frame>
    <description>Fasting urine F2alpha isoprostane/Cr ratio. Urine isoprostanes were measured by ELISA (Oxford Biomedical Research).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic Variability</measure>
    <time_frame>4 weeks</time_frame>
    <description>Glycemic variability as measured by the standard deviation (SD) of the glucose levels from the iPro continuous glucose monitoring system (CGMS)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Impaired Glucose Tolerance</condition>
  <condition>Oxidative Stress</condition>
  <condition>Prediabetes</condition>
  <condition>Impaired Fasting Glucose</condition>
  <arm_group>
    <arm_group_label>Low GI diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>low glycemic index diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High GI diet placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>high glycemic index diet plus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High GI diet NAC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>high glycemic index diet plus N-acetylcysteine</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>low glycemic index (LGI) diet</intervention_name>
    <description>Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable low glycemic index diet (glycemic index &lt;35) for 4 weeks with all food provided by the Human Nutrition Lab</description>
    <arm_group_label>Low GI diet</arm_group_label>
    <other_name>LGI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>high glycemic index (HGI) diet plus placebo (PLAC)</intervention_name>
    <description>Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index &gt;70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take placebo capsules (matching for active N-acetylcysteine (NAC) in arm 3) twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.</description>
    <arm_group_label>High GI diet placebo</arm_group_label>
    <other_name>HGI/PLAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high glycemic index diet plus N-acetylcysteine</intervention_name>
    <description>Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index &gt;70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take N-acetylcysteine (NAC) two 600 mg capsules twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.</description>
    <arm_group_label>High GI diet NAC</arm_group_label>
    <other_name>Diet</other_name>
    <other_name>N-acetylcysteine</other_name>
    <other_name>NAC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  impaired glucose tolerance (2 hour glucose 140-200 mg/dl after a standard 75 grams&#xD;
             oral glucose tolerance test [OGTT]) or&#xD;
&#xD;
          -  fasting glucose 100-115 mg/dl and 2 hour glucose &gt; 100 mg/dl after a standard OGTT&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  diabetes or taking diabetes medications&#xD;
&#xD;
          -  fasting glucose &gt;115 mg/dl&#xD;
&#xD;
          -  alanine aminotransferase (ALT) &gt;1.5 times the upper limit of normal&#xD;
&#xD;
          -  hematocrit &lt;33%&#xD;
&#xD;
          -  serum creatinine &gt;1.5 men or &gt;1.3 women&#xD;
&#xD;
          -  multiple food allergies or intolerances&#xD;
&#xD;
          -  other serious medical or inflammatory conditions&#xD;
&#xD;
          -  pregnancy or lactation&#xD;
&#xD;
          -  smoke or use tobacco&#xD;
&#xD;
          -  take medications that affect insulin sensitivity and secretion (niacin, diabetes&#xD;
             medications or glucocorticoids) or inflammation (anti-inflammatories such as&#xD;
             ibuprofen, naprosyn, aspirin)&#xD;
&#xD;
          -  significant gastroesophageal reflux (heartburn), swallowing problems or stomach&#xD;
             ulcers, including those taking medication for these indications&#xD;
&#xD;
          -  taking or having taken another investigational drug within the past 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristina M Utzschneider, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Puget Sound Health Care System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>June 29, 2011</study_first_submitted>
  <study_first_submitted_qc>June 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2011</study_first_posted>
  <results_first_submitted>May 22, 2020</results_first_submitted>
  <results_first_submitted_qc>August 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 12, 2020</results_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>impaired glucose tolerance</keyword>
  <keyword>prediabetes</keyword>
  <keyword>dietary glycemic index</keyword>
  <keyword>beta-cell function</keyword>
  <keyword>insulin secretion</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>glycemic variability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 2, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT01386645/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Low GI Diet</title>
          <description>low glycemic index diet&#xD;
low glycemic index diet: Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable low glycemic index diet (glycemic index &lt;35) for 4 weeks with all food provided by the Human Nutrition Lab</description>
        </group>
        <group group_id="P2">
          <title>High GI Diet Placebo</title>
          <description>high glycemic index diet plus placebo&#xD;
high glycemic index diet plus placebo: Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index &gt;70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take placebo capsules (matching for active N-acetylcysteine (NAC) in arm 3) twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.</description>
        </group>
        <group group_id="P3">
          <title>High GI Diet NAC</title>
          <description>high glycemic index diet plus N-acetylcysteine&#xD;
high glycemic index diet plus N-acetylcysteine: Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index &gt;70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take N-acetylcysteine (NAC) two 600 mg capsules twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low GI Diet</title>
          <description>low glycemic index diet&#xD;
low glycemic index diet: Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable low glycemic index diet (glycemic index &lt;35) for 4 weeks with all food provided by the Human Nutrition Lab</description>
        </group>
        <group group_id="B2">
          <title>High GI Diet Placebo</title>
          <description>high glycemic index diet plus placebo&#xD;
high glycemic index diet plus placebo: Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index &gt;70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take placebo capsules (matching for active N-acetylcysteine (NAC) in arm 3) twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.</description>
        </group>
        <group group_id="B3">
          <title>High GI Diet NAC</title>
          <description>high glycemic index diet plus N-acetylcysteine&#xD;
high glycemic index diet plus N-acetylcysteine: Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index &gt;70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take N-acetylcysteine (NAC) two 600 mg capsules twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="17"/>
            <count group_id="B4" value="53"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.2" spread="7.0"/>
                    <measurement group_id="B2" value="50.6" spread="10.3"/>
                    <measurement group_id="B3" value="51.2" spread="11.0"/>
                    <measurement group_id="B4" value="53.0" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.5" spread="4.7"/>
                    <measurement group_id="B2" value="32.4" spread="6.4"/>
                    <measurement group_id="B3" value="32.7" spread="8.0"/>
                    <measurement group_id="B4" value="32.5" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disposition Index</title>
        <description>The disposition index generated from an intravenous glucose tolerance test (insulin sensitivity x the acute insulin response to intravenous glucose) is a measure of beta-cell function.</description>
        <time_frame>4 weeks</time_frame>
        <population>1 participant in the LGI group ate before the second IVGTT and was excluded. One participant in the HGI/PLAC group could not get a second IV and we were unable to perform the IVGTT.</population>
        <group_list>
          <group group_id="O1">
            <title>Low GI Diet</title>
            <description>low glycemic index diet&#xD;
low glycemic index diet: Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable low glycemic index diet (glycemic index &lt;35) for 4 weeks with all food provided by the Human Nutrition Lab</description>
          </group>
          <group group_id="O2">
            <title>High GI Diet Placebo</title>
            <description>high glycemic index diet plus placebo&#xD;
high glycemic index diet plus placebo: Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index &gt;70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take placebo capsules (matching for active N-acetylcysteine (NAC) in arm 3) twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.</description>
          </group>
          <group group_id="O3">
            <title>High GI Diet NAC</title>
            <description>high glycemic index diet plus N-acetylcysteine&#xD;
high glycemic index diet plus N-acetylcysteine: Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index &gt;70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take N-acetylcysteine (NAC) two 600 mg capsules twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.</description>
          </group>
        </group_list>
        <measure>
          <title>Disposition Index</title>
          <description>The disposition index generated from an intravenous glucose tolerance test (insulin sensitivity x the acute insulin response to intravenous glucose) is a measure of beta-cell function.</description>
          <population>1 participant in the LGI group ate before the second IVGTT and was excluded. One participant in the HGI/PLAC group could not get a second IV and we were unable to perform the IVGTT.</population>
          <units>unitless</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="708" lower_limit="618" upper_limit="1244"/>
                    <measurement group_id="O2" value="793" lower_limit="594" upper_limit="1257"/>
                    <measurement group_id="O3" value="791" lower_limit="689" upper_limit="1215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine F2alpha Isoprostanes</title>
        <description>Fasting urine F2alpha isoprostane/Cr ratio. Urine isoprostanes were measured by ELISA (Oxford Biomedical Research).</description>
        <time_frame>4 weeks</time_frame>
        <population>Adults with prediabetes after 4 weeks on study interventions.</population>
        <group_list>
          <group group_id="O1">
            <title>Low GI Diet</title>
            <description>low glycemic index diet&#xD;
low glycemic index diet: Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable low glycemic index diet (glycemic index &lt;35) for 4 weeks with all food provided by the Human Nutrition Lab</description>
          </group>
          <group group_id="O2">
            <title>High GI Diet Placebo</title>
            <description>high glycemic index diet plus placebo&#xD;
high glycemic index diet plus placebo: Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index &gt;70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take placebo capsules (matching for active N-acetylcysteine (NAC) in arm 3) twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.</description>
          </group>
          <group group_id="O3">
            <title>High GI Diet NAC</title>
            <description>high glycemic index diet plus N-acetylcysteine&#xD;
high glycemic index diet plus N-acetylcysteine: Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index &gt;70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take N-acetylcysteine (NAC) two 600 mg capsules twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.</description>
          </group>
        </group_list>
        <measure>
          <title>Urine F2alpha Isoprostanes</title>
          <description>Fasting urine F2alpha isoprostane/Cr ratio. Urine isoprostanes were measured by ELISA (Oxford Biomedical Research).</description>
          <population>Adults with prediabetes after 4 weeks on study interventions.</population>
          <units>ng/mg</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.51" lower_limit="1.94" upper_limit="3.81"/>
                    <measurement group_id="O2" value="3.35" lower_limit="2.35" upper_limit="6.40"/>
                    <measurement group_id="O3" value="3.43" lower_limit="2.53" upper_limit="6.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glycemic Variability</title>
        <description>Glycemic variability as measured by the standard deviation (SD) of the glucose levels from the iPro continuous glucose monitoring system (CGMS)</description>
        <time_frame>4 weeks</time_frame>
        <population>Adults with prediabetes with useable iPro CGMS data after the 4 week intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Low GI Diet</title>
            <description>low glycemic index diet&#xD;
low glycemic index diet: Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable low glycemic index diet (glycemic index &lt;35) for 4 weeks with all food provided by the Human Nutrition Lab</description>
          </group>
          <group group_id="O2">
            <title>High GI Diet Placebo</title>
            <description>high glycemic index diet plus placebo&#xD;
high glycemic index diet plus placebo: Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index &gt;70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take placebo capsules (matching for active N-acetylcysteine (NAC) in arm 3) twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.</description>
          </group>
          <group group_id="O3">
            <title>High GI Diet NAC</title>
            <description>high glycemic index diet plus N-acetylcysteine&#xD;
high glycemic index diet plus N-acetylcysteine: Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index &gt;70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take N-acetylcysteine (NAC) two 600 mg capsules twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.</description>
          </group>
        </group_list>
        <measure>
          <title>Glycemic Variability</title>
          <description>Glycemic variability as measured by the standard deviation (SD) of the glucose levels from the iPro continuous glucose monitoring system (CGMS)</description>
          <population>Adults with prediabetes with useable iPro CGMS data after the 4 week intervention.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.20" spread="1.03"/>
                    <measurement group_id="O2" value="19.67" spread="1.57"/>
                    <measurement group_id="O3" value="17.69" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks</time_frame>
      <desc>Participants were asked about any problems related to their general health, heart, lungs, gastrointestinal system, neurologic system, urinary system and musculoskeletal system at the screening visit and at the end of the control and intervention diets using a systematic screening form. Adverse events were also reported by participants as they occurred.</desc>
      <group_list>
        <group group_id="E1">
          <title>Low GI Diet</title>
          <description>low glycemic index diet&#xD;
low glycemic index diet: Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable low glycemic index diet (glycemic index &lt;35) for 4 weeks with all food provided by the Human Nutrition Lab</description>
        </group>
        <group group_id="E2">
          <title>High GI Diet Placebo</title>
          <description>high glycemic index diet plus placebo&#xD;
high glycemic index diet plus placebo: Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index &gt;70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take placebo capsules (matching for active N-acetylcysteine (NAC) in arm 3) twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.</description>
        </group>
        <group group_id="E3">
          <title>High GI Diet NAC</title>
          <description>high glycemic index diet plus N-acetylcysteine&#xD;
high glycemic index diet plus N-acetylcysteine: Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index &gt;70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take N-acetylcysteine (NAC) two 600 mg capsules twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastroenteritis</sub_title>
                <description>Participant did not perform proper food handling and developed food poisoning with acute nausea, vomiting and diarrhea.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>cracked tooth</sub_title>
                <description>Participant reported that he cracked a tooth while eating broccoli that he said had something hard in it.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Some of the iPro CGMS devices failed to record or were dislodged. Thus, the number of participants with useable data for the CGMS variability data is less than the total enrolled.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kristina Utzschneider</name_or_title>
      <organization>VA Puget Sound Hlthcare System</organization>
      <phone>206-277-3568 ext 6-3568</phone>
      <email>kutzschn@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

